



**BTOG Masterclass – Molecular Subtypes beyond EGFR, ALK, ROS1**  
**Thursday 14<sup>th</sup> January 2021**  
**17:30 to 18:30**

**Aims:** to educate delegates on benefits of next generation sequencing (NGS) genotyping to identify rare variants for NHS-reimbursed therapies, compassionate use programmes and trials enrolment. All data will pertain to advanced NSCLC.

**Chair:** Professor Sanjay Popat

<b>17:30</b>	<b>Introduction</b>	<b>Sanjay Popat</b>
<b>17:31</b>	BRAF, KRAS, & insertion mutations you need to know about	<b>Raffaele Califano</b>
<b>17:46</b>	Splices and fusions you need to know about	<b>Alastair Greystoke</b>
<b>18:01</b>	How will we find suitable patients?	<b>Rachel Butler</b>
<b>18:16</b>	Q&A	
<b>18:30</b>	Close	

**Declarations**

1. BTOG confirms that all speakers will introduce themselves and will include as their 1<sup>st</sup> slide a declaration of conflict of interests and this will be visible to attendees.
2. BTOG confirms there will be a clear view of each speaker's slides. Each speaker will talk to the slides and their voice will accompany the slide discussion (where applicable).
3. BTOG confirms that participants viewing the educational presentations live will be able to submit questions and comments via live webinar chat.
4. BTOG confirms that if RCP approves this live webinar BTOG will provide access via BTOG's online resources and note that CPD will apply to the archived version for four weeks after the event date – we will ensure participants viewing the full archived version will be awarded the appropriate CPD and be issued a certificate of attendance.

## Biographies

**Professor Rachel Butler MBE** is the Head of the Bristol Genetic diagnostic laboratory, and Operational Director of the South West Genomics Laboratory Hub. The accredited laboratory provides genetic diagnostic analyses for rare diseases, cancer genomics, and now pharmacogenomics, handling over 30,000 samples each year. Rachel is actively developing the regions portfolio of genomic services for cancer in response to clinical demand and working with local teams to embed these into clinical practice. Rachel has previously led on the CRUK's Stratified Medicine Programme and been a grant holder for a number of stratified medicine clinical trials. She is currently the co-Chair of the National Genomic Test Directory Evaluation Group for Cancer. She was awarded an MBE in 2017 for services to Genomics in Wales and the UK.

**Dr Raffaele Califano** graduated in Medicine and Surgery, summa cum laude, from the University of Perugia, Italy, in 2003 and completed his specialist training in Medical Oncology, summa cum laude, in 2007. He then worked as Clinical Research Fellow with the lung and melanoma team at The Christie, being an investigator for several clinical trials in lung cancer and melanoma and developing a particular interest in molecularly driven clinical trials in lung cancer. Dr Califano has been a consultant at The Christie and University Hospital of South Manchester since 2012 and specialises in the treatment of thoracic malignancies. Dr Califano is the author of several papers published in indexed peer-reviewed international journals and he has been an invited speaker to several national and international oncology meetings.

**Dr Alastair Greystoke** is Clinical Senior Lecturer and Honorary Consultant at the Newcastle University and the Northern Centre for Cancer Care. Dr Greystoke joined Newcastle University and the Northern Centre for Cancer Care in 2014 after 8 years spent at the University of Manchester/Christie NHS Trust. He is one of 3 consultants that run the Sir Bobby Robson Early Clinical Trials Centre at the Freeman hospital in Newcastle and has a special interest in the development of new anti-cancer drugs for patients with thoracic malignancies. In addition, he is the Joint Chief Investigator of the CONCORDE platform (adding in new drugs to radical radiotherapy in NSCLC), Clinical Lead for Cancer for the Yorkshire, Hull and North East England Genomic Laboratory Hub and he leads the Pharmacodynamic Biomarker team at the Northern Institute for Cancer Research, Newcastle University.

**Professor Sanjay Popat** is Consultant Thoracic Medical Oncologist at the Royal Marsden Hospital and Professor of Thoracic Oncology at the Institute of Cancer Research. Professor Popat has published in the fields of genetics, therapeutic biomarkers and medical oncology. He has been awarded nationally and internationally competitive prizes for his research, in addition to 4 research fellowships. He has published over 150 papers and is an active member of the EORTC Lung Group, has been elected to the Foundation Council of ETOP and is past chair of the UK NCRI Lung Cancer CSG Advanced Diseases Subgroup. Professor Popat joined the BTOG Steering Committee in 2010 and was elected Chair of the Steering Committee in 2013.